BLOOD,26APRIL2012 VOLUME119,NUMBER17
wasthemosteffectiveintermsofproliferationandcytokineproduction.23Wethereforeselectedthisconstructforclinicaltestingandreportheretheresultsofasmallpilottrialtestingthis“third-generation”CAR.
Methods
Clinicaltrialprotocol
ThisclinicalprotocolwasapprovedbytheFredHutchinsonCancerResearchCenterInstitutionalReviewBoard,UniversityofWashingtonInstitutionalBiosafetyCommittee,andtheNationalInstitutesofHealthRecombinantDNAAdvisoryCommittee,andissupportedbytheUnitedStatesFoodandDrugAdministration(BB-IND13390).Thisstudyisregisteredatdoc.guandang.net rmeddiagnosisofCD20 MCLorindolentB-celllymphoma,hadrelapsedorrefractorydiseaseafteratleastonepriorchemotherapy,weredeemednottobecandidatesfor(orrefused)SCT,andhadserologicevidenceofpriorEpstein-Barrvirus(EBV)exposure(becausetheTM-LCLcelllineusedinT-cellcultureisEBV-transformed).Patientswereexcludediftheyhadreceived udarabineorcladribinewithin2yearsbeforeapheresis(thesedrugscauseaprotractedlymphopeniathatcouldpotentiallyimpairthenumberorfunctionofTcellscollectedduringapheresis),anti-CD20Absorchemotherapywithin4weeksofT-cellinfusions;hadlymphnodeslargerthan5cmormorethan5000circulatinglymphomacellsintheperipheralbloodatthetimeofT-cellinfusions,previousallogeneicSCT,orhumananti–mouseAbseropositivity.
Patientsunderwentapheresistocollectperipheralbloodmononuclearcells(PBMCs)andcouldthenreceivecytoreductivechemotherapyfordiseasecontrolordebulkingduringthe2-the3-monthperiodofT-cellexpansion,atthediscretionofthereferringphysician.ReleasecriteriaforexvivoexpandedTcellswereasfollows:sterilitybyUnitedStatesPharmacopeia,fungal,andmycoplasmatesting,negativeGramstain,endotoxinlessthan5U/kg,morethan70%viabilitybyTrypanBlueexclusion,CD3 andTCR by owcytometry,IL-2–dependentgrowth,andCD20-speci ccytotoxicityofmorethan20%lysisat100:1E:Tratio.Patientssubsequentlyreceivedcyclophosphamide(CY)1000mg/m2intra-venouslytoachievelymphodepletion2daysbeforestartingaseriesof3infusionsofautologousCD20-speci cTcells2to5daysapartinescalatingdoses(108,109,and3.3 109cells/m2),followedby14daysofsubcutaneouslow-dose(250000IU/m2)IL-2injectionstwicedaily.Anexcisionalbiopsyofapalpablelymphnodeandabonemarrowbiopsywereperformedoneachpatient24to48hoursafterthe nalT-cellinfusion.Anotherbonemarrowbiopsyatthe1-monthtimepointwasoptional.Patientsunderwentclinicalfollow-uptoevaluatetoxicitiesrelatedtotherapy,whichwereassessedaccordingtoNationalInstitutesofHealthCommonTerminologyCriteriaforAdverseEventsVersion3.0(doc.guandang.net).ClinicalresponseswereassessedaccordingtoInterna-tionalWorkingGroupcriteria.25
Modi cationandexpansionofCD20-speci cTcells
CD20-speci cTcellsweregeneratedaspreviouslydescribed.15,23PatientPBMCswereactivatedwithOKT3andIL-2,and4dayslaterwereelec-troporatedwiththeL29.19.1plasmid,23whichencodesaLeu16(murineanti–humanCD20)scFvfusedtoahumanIgG1CH2-CH3hinge,CD4trans-membrane,intracellularCD28(withmutateddileucinemotif)26andCD137(4-1BB)costimulatorydomains,andCD3 ,underthecontroloftheCMVimmediate-earlypromoter,hereafterdenotedasthe CD20-28-BB- CAR,aswellasaneomycinresistancegeneunderthecontrolofanSV40promoter.Transfectedcellswererestimulatedin12-to15-daycyclesusingarapidexpansionprotocol15,27andselectedwithG418duringthe rst,third,andfourthstimulationcycles.G418-resistantcellsweretransferredfrom askstoculturebagsuntilthetargetcelldosewasreached.
CD20-CARTHERAPYFORNHL3941
Insomeinstances,batchesofcellswerecryopreservedduringexpansionandthawedbeforeinfusion.Cytotoxicityassays
Standard5-hourchromiumreleaseassayswereperformedaspreviouslydescribed,15usingthefollowingtargets:EL4(negativecontrol),EL4-CD20(EL4cellstransfectedtoexpressCD20),Granta(CD20 MCLline),andDaudi(CD20 Burkittlymphomacellline).Flowcytometry
ImmunophenotypesofexvivoexpandedTcellswereassessedbythawingandwashingpre-infusionTcells,andincubated30minutesat4°Cwiththefollowingantibodies,allfromBDBiosciences:anti-CD3–PE,anti-CD4–FITC,anti-CD8–FITC,anti-CD25–PE,anti-CD27–FITC,anti-CD28–FITC,anti-CD44–PE,anti-CD45RA–FITC,anti-CD45RO–FITC,anti-CD56–PE,anti-CD57–FITC,anti-CD62–PE,anti-CD183(CXCR3)–PE,andanti-CD197(CCR7)–FITC.CellsurfaceIL-15andIL-15R weremeasuredbylabelingthawed,washedpatientPBMCsfrombaselineandserialpost-CYtimepointswitheitheranti-CD3–PEoranti-CD14–PE(BDBiosciences)andeitheranti–IL-15–FITC(R&DSystems)oranti–IL-15R –FITC(eBioscience)andpropidiumiodide(BDBiosciences).CellswerewashedwithPBSplus0.5%FCS,andapproximately20000eventswereacquiredonaFACSCaliburmachine(BDBiosciences).DatawereanalyzedusingFlowJoVersion7.6.1software(TreeStar).CARexpressionwasassessedbyFACSusingFITC-conjugatedgoatanti–mouseIgGF(ab )2orPE-conjugatedgoatanti–humanIgGFc(JacksonImmunoResearchLaboratories)aspreviouslydescribed.15,23Lymphocytesubsetsinseriallycollectedperipheralbloodsampleswereanalyzedusingmultiparameter owcytometryaspreviouslydescribed.15
QuantitativePCRtodetectmodi edTcells
PatientPBMCscollectedatbaselineandatserialtimepointsafterT-cellinfusionswerecollectedandseparatedbyFicollcentrifugationandthencryopreserved.BatchedcellswerethawedandgenomicDNAwashar-vestedusingaDNeasyBloodandTissueKit(QIAGEN).TheCARtransgenewasdetectedbyperformingquantitativePCRaspreviouslydescribed,15usingeitheraprimeramplifyinga111-bpfragmentspanningthejunctionoftheCD4transmembraneregionandadjacentCD28domain(forwardprimer:5 -TGGGCTAGGCATCTTCTTCA-3 ,reverseprimer:5 -GCATAGGGCTGGTAATGCTT-3 ,probe:5 -FAM-CACAGTGACTA-CATGAACATGAC-TAMRA-3 ),oraprimeramplifyinga113-bpfrag-mentspanningthejunctionofCD137domainandadjacentCD3 chain(forwardprimer:5 -GAAGAAGGAGGATGTGAACT-3 ,reverseprimer:5 -TCCTCTCTTCGTCCTAGATT-3 ,probe:5 -FAM-AGGGCCAGAAC-CAGCTCTATAA-TAMRA-3 ).Quantitativereal-timePCRwasperformedintriplicateusingTaqManUniversalPCRMasterMix(AppliedBiosys-tems),ina7900HTFastReal-TimePCRSystem(AppliedBiosystems).CopynumberspermicrogramofgenomicDNA,generatedfromastandardcurveof10-foldserialdilutionsofpuri edplasmid,wereusedtocalculatethepercentageofCAR cellsamongPBMCs,assuming1copy/cell,28basedon:1 ggenomicDNA/6.7pgDNApercell 1.49 105cells.Immuneresponseassays
Twohumoralimmuneresponseassayswereperformed:anELISAassaydetectingAbagainsttheLeu16murineanti-CD20AbandaFACSassaydetectingAbagainstHEK-293cellstransfectedwiththeL29.19.1vector.AcellularimmuneresponseassaywasperformedtodetectTcellsrespondingtostimulationwithcellsexpressingthetransgeneproducts.DetailsofimmuneresponseassaysareprovidedinsupplementalMethods(availableontheBloodWebsite;seetheSupplementalMaterialslinkatthetopoftheonlinearticle).Telomereanalysis
PatientPBMCsobtainedatapheresiswerethawed,washed,andseparatedoveraFicollgradient,andpositivelyCD3-selectedbyMACS(Miltenyi
A universal strategy for adoptive immunotherapy of...lymphoma, where all tumor cells express, CD19, ...To interrogate antigen-specific cytolytic potential,...
γδ T cells a better choice for the adoptive immunotherapy of lymphoid malignancies_医学_高等教育_教育专区。Anti-γδ TCR antibody-expanded γδ T ...
Ex vivo gene transfer for improved adoptive immunotherapy of cancer 隐藏>>...Her-2/neu breast cancer cell line and CD20-positive lymphoma (49,50). ...
Differences in the recognition of tumor-specific CD8+ T cells derived from...Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated ...
Key words: CIK cells; adoptive immunotherapy; ...[37] or their engineering to produce specific ...CD8+ NK-T cells in the treatment of lymphoma....
Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta new...lymphoma cell line (Daudi), T cell lymphoma cell line(Jurkat) non-small ...
(1993) [Study of adoptive immunotherapy for metastatic renal cell carcinoma ...(CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing ...
graft-versusleukemia/lymphoma; GVT, graft-versus-tumor, hematopoietic stem ...Adoptive T cell cancer immunotherapy is based on the premise that T cells ...
Antitumor Immunity by T-Cell Adoptive Immunotherapy...antigen-specific T cells that facilitate their ...lymphoma, are providing opportunities to broaden ...
? ? ? Burkitt’s lymphoma B-cell lymphoma in ...Differentiation- specific antigens ? ? CALLA (CD... (Tumors secrete factors TGFb) IMMUNOTHERAPY ? ...
热门文档